News

Doctors involved in treating children with antineutrophil cytpolasmic antibody (ANCA)-associated vasculitis (AAV) have revealed the unmet need for evidence-based treatment guidelines that improve the management and outcomes of their patients, a new international survey revealed. The study, “Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists…

International collaboration on research into rare diseases like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is fundamental to improving the health and lives of patients, a new study suggests. The review, titled “The importance of international collaboration for rare diseases research: a European perspective,” was published in the journal…

In patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), Rituxan (rituximab) may lead to general decrease in antibody levels, increasing their risk for infections, finds a single-center retrospective study. The study, “Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis,” appeared in…

Improvements in patient care and in available therapies the past 15 years have led to an improvement of more than two years in the survival of Lithuanian patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), a new study shows. The study “Clinical characteristics and long-term…

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application  seeking approval of Truxima (CT-P10), Celltrion‘s biosimilar to Rituxan (rituximab), for the same indications as Rituxan. The FDA’s decision is expected by the first quarter of 2018. If approved, Truxima will become available for two…

Patients with eosinophilic granulomatosis with polyangiitis (EGPA, or Churg-Strauss syndrome) who receive scheduled Rituxan (rituximab) therapy have lower relapse rates than those who are given Rituxan only during a relapse, a new study shows. The study titled, “Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis,” was…

A new study suggests that patients with ANCA-associated vasculitis (AAVs) may be at an increased risk of developing ischemic stroke and coronary artery disease. The study, “Risk of coronary artery disease and ischemic stroke in patients with ANCA-associated vasculitis. A French population-based study,” was…

Patients with granulomatosis with polyangiitis (GPA) — formerly known as Wegener’s granulomatosis — with severe inflammation in the eyes may significantly benefit from the anti-CD20 antibody Rituxan (rituximab). In the study, “Rituximab Induction and Maintenance Treatment in Patients…

More than one detection technique may be necessary to confirm the diagnosis of granulomatosis with polyangiitis (GPA), a type of vasculitis, researchers found. The study found that samples that had been previously considered negative for GPA when tested for the presence of ANCA proteins were actually positive when researchers used…

The Phase 3 ADVOCATE trial, evaluating ChemoCentryx‘s investigational drug avacopan (formerly CCX168) for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is now enrolling participants. The update is part of the company’s financial report for the second quarter of 2017. The study (NCT02994927), which aims to evaluate the safety…